Small Molecule Inhibitors of the p53-MDM2

Author(s): Chun-Qi Hu, Yong-Zhou Hu

Journal Name: Current Medicinal Chemistry

Volume 15 , Issue 17 , 2008

Become EABM
Become Reviewer
Call for Editor


Recent researches have discovered that MDM2 (murine double minute 2, or HDM2 for the human congener) protein is the main negative regulator of p53, which is an attractive therapeutic target in oncology because its tumor-suppressor activity which can be stimulated to eradicate tumor cells. Inhibiting the p53 – MDM2 interaction is a promising approach for activating p53, because this association is well characterized at the structural and biological levels. A number of drug screening approaches and technologies have been used to identity novel inhibitors of the p53-MDM2 interaction. This review will detail the development history of MDM2 protein and the p53-MDM2 interaction, the major classes of novel small-molecular p53-MDM2 binding inhibitors, key medicinal action with the protein-protein interaction and in vitro or in vivo biological activtiies.

Keywords: MDM2, p53-MDM2 interaction, SAR, small molecular inhibitors, therapeutics/drugs

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [1720 - 1730]
Pages: 11
DOI: 10.2174/092986708784872375
Price: $65

Article Metrics

PDF: 9